Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) announced that the group had launched its RediTrex® range of pre-filled syringes. The new product is launched across the nation. The pre-filled syringes can be used to treat conditions like active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis. In addition, the new product is safe and simple to use.
RediTrex® has received the necessary FDA approval. The same is designed so that it enables easy handling and effortless dosing, which results in a spike in the efficacy rate. It is understood that RediTrex® treats patients with conditions like severe, active rheumatoid arthritis and polyarticular juvenile idiopathic arthritis. Available in eight dosages, RediTrex® is designed for subcutaneous injection, informed A.J. Kazimi, CEO of Cumberland Pharmaceuticals, Inc.
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and rheumatology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative, for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease.
Market Reaction:
On Friday, CPIX stock jumped 1.11% at $2.73 with more than 15k shares, compared to its average volume of 23K shares. The stock has moved within a range of $2.6700 – 2.7300 after opening the trade at $2.67.
